stockrowRegeneron Pharmaceuticals, Inc.
REGN Healthcare Biotechnology
Regeneron Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, up 0.99% from fiscal 2024.
- Revenue
- +36.3%
- EPS
- +36.0%
- Free cash flow
- +3.85%
- Total debt
- −26.6%
Quarter to September 2026, against a year earlier
Follow REGN
Alert me
Regeneron Pharmaceuticals, Inc. (REGN) EPS (diluted)
Regeneron Pharmaceuticals, Inc.'s EPS (diluted) for fiscal 2025 was $41.48, up 8.19% from $38.34 in fiscal 2024. Over the twelve months to 30 September 2026 it was $45.29. Over the past ten years it has ranged from $5.52 (fiscal 2015) to $71.97 (fiscal 2021); the current reading is higher than 91% of that period. Regeneron Pharmaceuticals, Inc. ranks 5th of 580 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $41.48 | 8.19% |
| FY2024 | $38.34 | 10.27% |
| FY2023 | $34.77 | (9.03%) |
| FY2022 | $38.22 | (46.89%) |
| FY2021 | $71.97 | 135.81% |
| FY2020 | $30.52 | 65.33% |
| FY2019 | $18.46 | (13.29%) |
| FY2018 | $21.29 | 105.90% |
| FY2017 | $10.34 | 34.29% |
| FY2016 | $7.70 | 39.49% |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | $18.45 | 50.86% |
| Jun 2026 | $12.23 | 81.19% |
| Mar 2026 | $6.75 | (14.12%) |
| Dec 2025 | $7.86 | (42.29%) |
| 43 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| REGN Regeneron Pharmaceuticals, Inc. | $45.29 |
| ARGX argenex SE compare | $28.66 |
| VRTX Vertex Pharmaceuticals Incorporated compare | $15.54 |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | $5.68 |
| RPRX Royalty Pharma PLC compare | $1.40 |
| GMAB Genmab A/S Sponsored ADR compare | $1.27 |
| ROIV Roivant Sciences Ltd. compare | −$0.53 |
| MRNA Moderna, Inc. compare | −$7.99 |
| RVMD Revolution Medicines, Inc. compare | −$9.11 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on REGN
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement